Off-label use of atypical antipsychotics in personality disorders
- PMID: 21933032
- DOI: 10.1517/14656566.2011.608351
Off-label use of atypical antipsychotics in personality disorders
Abstract
Introduction: Personality disorders are among the most persistent and challenging disorders to treat within psychiatry. There is emerging evidence that some personality disorders, particularly borderline personality disorder and, to a lesser extent, schizotypal personality disorder, may benefit from treatment with atypical antipsychotics as well as mood stabilizers. This review examines the evidence for atypical antipsychotics for personality disorders and discusses strengths and limitations of this approach.
Areas covered: Searches of Medline and PsycInfo yielded 57 articles related to use of atypical antipsychotics for treatment of personality disorders. Most were relatively small randomized, controlled trials examining atypical antipsychotics for borderline personality disorder; however, the search also yielded two Cochrane reviews examining pharmacotherapy for borderline personality disorder and antisocial personality disorder as well as three other meta-analyses.
Expert opinion: There is some evidence that atypical antipsychotics are effective for treating symptom domains in personality disorders, in particular psychotic-like symptoms, impulsivity, aggression and anger. There is no evidence that they improve overall illness severity. Given the high rate of comorbidity between personality disorders and axis I disorders, atypical antipsychotics are best used when these symptom domains are prominent and there is a comorbid axis I condition for which an atypical antipsychotic is indicated.
Similar articles
-
Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms.J Pers Disord. 2009 Apr;23(2):156-74. doi: 10.1521/pedi.2009.23.2.156. J Pers Disord. 2009. PMID: 19379093 Review.
-
Differential effectiveness of antipsychotics in borderline personality disorder: meta-analyses of placebo-controlled, randomized clinical trials on symptomatic outcome domains.J Clin Psychopharmacol. 2011 Aug;31(4):489-96. doi: 10.1097/JCP.0b013e3182217a69. J Clin Psychopharmacol. 2011. PMID: 21694626
-
Antipsychotics, antidepressants, anticonvulsants, and placebo on the symptom dimensions of borderline personality disorder: a meta-analysis of randomized controlled and open-label trials.J Clin Psychopharmacol. 2011 Oct;31(5):613-24. doi: 10.1097/JCP.0b013e31822c1636. J Clin Psychopharmacol. 2011. PMID: 21869691
-
Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials.Int Clin Psychopharmacol. 2006 Nov;21(6):345-53. doi: 10.1097/01.yic.0000224784.90911.66. Int Clin Psychopharmacol. 2006. PMID: 17012981
-
Efficacy and tolerability of pharmacotherapies for borderline personality disorder.CNS Drugs. 2008;22(8):671-92. doi: 10.2165/00023210-200822080-00005. CNS Drugs. 2008. PMID: 18601305 Review.
Cited by
-
Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry.J Neural Transm (Vienna). 2022 Nov;129(11):1353-1365. doi: 10.1007/s00702-022-02542-0. Epub 2022 Sep 7. J Neural Transm (Vienna). 2022. PMID: 36070009
-
A Patient-Clinician Discussion of Current Challenges in Schizophrenia Part 1: Addressing Daily Functioning and Cognitive Impairments Associated with Schizophrenia [Podcast].Neuropsychiatr Dis Treat. 2023 Jun 2;19:1331-1338. doi: 10.2147/NDT.S419177. eCollection 2023. Neuropsychiatr Dis Treat. 2023. PMID: 37292181 Free PMC article.
-
Comparative risk of new-onset diabetes following commencement of antipsychotics in New Zealand: a population-based clustered multiple baseline time series design.BMJ Open. 2019 Feb 21;9(2):e022984. doi: 10.1136/bmjopen-2018-022984. BMJ Open. 2019. PMID: 30796116 Free PMC article.
-
Antipsychotic off-label use in the 21st century: An enduring public health concern.Dialogues Clin Neurosci. 2025 Dec;27(1):1-12. doi: 10.1080/19585969.2025.2449833. Epub 2025 Jan 10. Dialogues Clin Neurosci. 2025. PMID: 39791867 Free PMC article. Review.
-
Prediction of antipsychotics efficacy based on a polygenic risk score: a real-world cohort study.Front Pharmacol. 2024 Mar 8;15:1274442. doi: 10.3389/fphar.2024.1274442. eCollection 2024. Front Pharmacol. 2024. PMID: 38523642 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources